Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety study of NNC0705-0002 in healthy volunteers
NL-OMON61505Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1 trial of NNC0705-0002, sponsored by Novo Nordisk. Primary endpoint: Primary endpoint(s). Started Aug 2026; status: recruiting.
02
Drugs
NNC0705-0002
Beyond the preview
Go deeper on NL-OMON61505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61505.